Targeting V(1A)-vasopressin receptors with [Arg(6), D-Trp(7,9), N(me)Phe(8)]-substance P (6-11) identifies a strategy to develop novel anti-cancer therapies

Ítems similars

• Increased gastrin-releasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg(6),D-Trp(7,9),N(me)Phe(8)]-substance P (6–11)-induced growth inhibition
  per: Waters, C M, et al.
  Publicat: (2003)
• [Arg(6), D-Trp(7,9), N(me)Phe(8)]-substance P (6–11) (antagonist G) inducesP-1 transcription and sensitizes cells to chemotherapy
  per: MacKinnon, A C, et al.
  Publicat: (2000)
• [Arg(6),D-Trp(7,9),N(me)Phe(8)]-substance P (6–11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism
  per: MacKinnon, A C, et al.
  Publicat: (1999)
• Metabolism of the broad-spectrum neuropeptide growth factor antagonist: [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance P.
  per: Jones, D. A., et al.
  Publicat: (1996)
• Single Nucleotide Polymorphisms in the Melanocortin His-Phe-Arg-Trp Sequences Decrease Tetrapeptide Potency and Efficacy
  per: Winget, Marshall D., et al.
  Publicat: (2019)